Novartis announces that the European Commission has approved its Cosentyx for use in the EU in adults with moderate to severe active hidradenitis suppurativa who have failed to respond to conventional systemic therapy.
This European approval is based on robust Phase III data showing that Cosentyx provided rapid symptom relief as early as week 4, with response rates continuing to improve for up to one year, with its known safety profile. .
Hidradenitis suppurativa is a chronic inflammatory disease of the skin resulting in painful and potentially disfiguring abscesses. Around 200,000 people in Europe are currently living with moderate to severe stages of the disease.
This article is originally published on boursorama.com
